A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease

PharmacoEconomics

Volumn 24, Issue 2, 2006, Pages 155-169

  Lamotte, Mark ^a,d   Annemans, Lieven ^a,b   Evers, Thomas ^c   Kubin, Maria ^c  

^a Health Economics and Disease Management   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c BAYER PHARMA AG   (Germany)

^d IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEATH; ECONOMIC EVALUATION; EUROPE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RISK FACTOR; SENSITIVITY ANALYSIS; STROKE; UNIVARIATE ANALYSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; EUROPE; HUMANS; MARKOV CHAINS; META-ANALYSIS; RISK FACTORS;

EID: 32644444957     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624020-00005     Document Type: Article

References (30)

1. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 136: 161-72
2. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313-6
3. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-35
4. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233-41
5. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optima Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62
6. Collaborative group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89-95
7. Eidelman RS, Herbert PR, Weisman SM, et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003; 163: 2006-10
8. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. Ann Intern Med 2002; 136: 157-60
9. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases: American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388-91
10. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-10
11. Euroaspire Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from Euroaspire II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72
12. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199-270
13. Collinson J, Flather MD, Fox KAA, et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST-elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). The PRAIS-UK investigators. Eur Heart J 2000; 21: 1450-7
14. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39
15. Department of Health. NHS reference costs [online]. Available from URL: http://www.dh.gov.uk/PolicyAndGuidance/Organ isationPolicy/FinanceAndPlanning/ NHSreferenceCosts/fs/en [Accessed 2004 Mar]
16. Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003; 20: 442-50
17. Personal Social Services Research Unit. Unit costs of health and social care 2003 [online]. Available from URL: http://www.pssru.ac.uk/pdf/uc2003/ uc2003_inflation.pdf [Accessed 2004 Mar]
18. Database of health care costs, Version 1.5. Barcelona: SOIKOS SL, 2004 Jan
19. Statistisches Bundesamt Deutschland [online]. Available from URL: http://www.destatis.de [Accessed 2004 Mar]
20. Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003; 21: 651-9
21. Istat.it. Documento non trovato [online]. Available from URL: http://www.istat.it/DATI/Rivalutazi/variaz33.html [Accessed 2004 Mar]
22. Instituto Nacional de Estadistica [online]. Available from URL: http://www.ine.es/inebase/cgi/um?M=/t25/p138&O=inebase [Accessed 2004 Jan]
23. British National Formulary [online]. Available from URL: http://www.bnf.org.uk/bnf/ [Accessed 2004 Mar]
24. Official tariffs from Jan 2004 provided by Bayer Healthcare AG
25. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-trade off utilities in survivors of myocardial infarction. Med Decis Making 1993; 13: 161-5
26. Tengs TO, Lin TH. A meta-analysis of quality of life estimates for stroke. Pharmacoeconomics 2003; 21: 191-200
27. Kuntz KM, Tsevat J, Goldman L, et al. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation 1996; 94: 957-65
28. Catherwood E, Fitzpatrick WD, Greenberg ML, et al. Cost-effectiveness of cardioversion and antiarrhythmic therapy in Socienonvalvular atrial fibrillation. Ann Intern Med 1999; 130: 625-36
29. Caro J, Klittich W, McGuire A, et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315: 1577-82
30. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-304